A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-10, Vol.27, p.vi437-vi437 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | vi437 |
|---|---|
| container_issue | |
| container_start_page | vi437 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Pacey, S. Blackhall, F. Garcia-Corbacho, J. Lipplaa, A. Fusi, A. Kumar, S. Hategan, M. Derham, J. Laviste, G. Halford, S. Foxton, C. McLeod, R. Wan, S. Talbot, D. |
| description | |
| doi_str_mv | 10.1093/annonc/mdw383.61 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw383_61</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419448849</els_id><sourcerecordid>S0923753419448849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3211-364c40fc8f924fddb6c28c9a383eb5cb7c94b3c150ec0993a5d2b8aa1e820f6c3</originalsourceid><addsrcrecordid>eNp1kM1KxDAUhYMoOP7sXeYFOpM0badxN8iogyOCqNuS3NwykTaRJDPiQ_mOVivqxtW5HPgOl4-QM86mnEkxU855B7PevIpaTCu-Rya8rGRWs4LvkwmTucjmpSgOyVGMz4yxSuZyQt4X9GWjItIVNX4IjKA6lax3NKateaO-pWmDNPkOg9K2s-mn80F19Gl5dXlPlTP067BuY7VNPtDd0GFSzuqhpOB7bd04_GrT5nfgdnnDZ_kfMGK37THZbzL6zhqatr0P8YQctKqLePqdx-TxcvlwcZ2t765WF4t1BiLnPBNVAQVroW5lXrTG6AryGqQazKAuQc9BFloALxkCk1Ko0uS6VopjnbO2AnFM2LgLwccYsG1egu1VeGs4az51N6PuZtTdVHxAzkcEh792FkMTwaIDNDYgpMZ4-z_8AZRZjYY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Pacey, S. ; Blackhall, F. ; Garcia-Corbacho, J. ; Lipplaa, A. ; Fusi, A. ; Kumar, S. ; Hategan, M. ; Derham, J. ; Laviste, G. ; Halford, S. ; Foxton, C. ; McLeod, R. ; Wan, S. ; Talbot, D.</creator><creatorcontrib>Pacey, S. ; Blackhall, F. ; Garcia-Corbacho, J. ; Lipplaa, A. ; Fusi, A. ; Kumar, S. ; Hategan, M. ; Derham, J. ; Laviste, G. ; Halford, S. ; Foxton, C. ; McLeod, R. ; Wan, S. ; Talbot, D.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw383.61</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2016-10, Vol.27, p.vi437-vi437</ispartof><rights>2016 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3211-364c40fc8f924fddb6c28c9a383eb5cb7c94b3c150ec0993a5d2b8aa1e820f6c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Pacey, S.</creatorcontrib><creatorcontrib>Blackhall, F.</creatorcontrib><creatorcontrib>Garcia-Corbacho, J.</creatorcontrib><creatorcontrib>Lipplaa, A.</creatorcontrib><creatorcontrib>Fusi, A.</creatorcontrib><creatorcontrib>Kumar, S.</creatorcontrib><creatorcontrib>Hategan, M.</creatorcontrib><creatorcontrib>Derham, J.</creatorcontrib><creatorcontrib>Laviste, G.</creatorcontrib><creatorcontrib>Halford, S.</creatorcontrib><creatorcontrib>Foxton, C.</creatorcontrib><creatorcontrib>McLeod, R.</creatorcontrib><creatorcontrib>Wan, S.</creatorcontrib><creatorcontrib>Talbot, D.</creatorcontrib><title>A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KxDAUhYMoOP7sXeYFOpM0badxN8iogyOCqNuS3NwykTaRJDPiQ_mOVivqxtW5HPgOl4-QM86mnEkxU855B7PevIpaTCu-Rya8rGRWs4LvkwmTucjmpSgOyVGMz4yxSuZyQt4X9GWjItIVNX4IjKA6lax3NKateaO-pWmDNPkOg9K2s-mn80F19Gl5dXlPlTP067BuY7VNPtDd0GFSzuqhpOB7bd04_GrT5nfgdnnDZ_kfMGK37THZbzL6zhqatr0P8YQctKqLePqdx-TxcvlwcZ2t765WF4t1BiLnPBNVAQVroW5lXrTG6AryGqQazKAuQc9BFloALxkCk1Ko0uS6VopjnbO2AnFM2LgLwccYsG1egu1VeGs4az51N6PuZtTdVHxAzkcEh792FkMTwaIDNDYgpMZ4-z_8AZRZjYY</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Pacey, S.</creator><creator>Blackhall, F.</creator><creator>Garcia-Corbacho, J.</creator><creator>Lipplaa, A.</creator><creator>Fusi, A.</creator><creator>Kumar, S.</creator><creator>Hategan, M.</creator><creator>Derham, J.</creator><creator>Laviste, G.</creator><creator>Halford, S.</creator><creator>Foxton, C.</creator><creator>McLeod, R.</creator><creator>Wan, S.</creator><creator>Talbot, D.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161001</creationdate><title>A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors</title><author>Pacey, S. ; Blackhall, F. ; Garcia-Corbacho, J. ; Lipplaa, A. ; Fusi, A. ; Kumar, S. ; Hategan, M. ; Derham, J. ; Laviste, G. ; Halford, S. ; Foxton, C. ; McLeod, R. ; Wan, S. ; Talbot, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3211-364c40fc8f924fddb6c28c9a383eb5cb7c94b3c150ec0993a5d2b8aa1e820f6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pacey, S.</creatorcontrib><creatorcontrib>Blackhall, F.</creatorcontrib><creatorcontrib>Garcia-Corbacho, J.</creatorcontrib><creatorcontrib>Lipplaa, A.</creatorcontrib><creatorcontrib>Fusi, A.</creatorcontrib><creatorcontrib>Kumar, S.</creatorcontrib><creatorcontrib>Hategan, M.</creatorcontrib><creatorcontrib>Derham, J.</creatorcontrib><creatorcontrib>Laviste, G.</creatorcontrib><creatorcontrib>Halford, S.</creatorcontrib><creatorcontrib>Foxton, C.</creatorcontrib><creatorcontrib>McLeod, R.</creatorcontrib><creatorcontrib>Wan, S.</creatorcontrib><creatorcontrib>Talbot, D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pacey, S.</au><au>Blackhall, F.</au><au>Garcia-Corbacho, J.</au><au>Lipplaa, A.</au><au>Fusi, A.</au><au>Kumar, S.</au><au>Hategan, M.</au><au>Derham, J.</au><au>Laviste, G.</au><au>Halford, S.</au><au>Foxton, C.</au><au>McLeod, R.</au><au>Wan, S.</au><au>Talbot, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors</atitle><jtitle>Annals of oncology</jtitle><date>2016-10-01</date><risdate>2016</risdate><volume>27</volume><spage>vi437</spage><epage>vi437</epage><pages>vi437-vi437</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdw383.61</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-10, Vol.27, p.vi437-vi437 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw383_61 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A38%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20I%20dose%20escalation%20study%20of%20the%20tolerability%20of%20the%20oral%20VEGFR%20and%20EGFR%20inhibitor%20vandetanib%20in%20combination%20with%20the%20oral%20MEK1/2%20inhibitor%20selumetinib%20in%20solid%20tumors&rft.jtitle=Annals%20of%20oncology&rft.au=Pacey,%20S.&rft.date=2016-10-01&rft.volume=27&rft.spage=vi437&rft.epage=vi437&rft.pages=vi437-vi437&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw383.61&rft_dat=%3Celsevier_cross%3ES0923753419448849%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753419448849&rfr_iscdi=true |